425 related articles for article (PubMed ID: 8351515)
61. Synthesis of phosphorothioate analogues of oligodeoxyribonucleotides and their antiviral activity against human immunodeficiency virus (HIV).
Matsukura M; Zon G; Shinozuka K; Stein CA; Mitsuya H; Cohen JS; Broder S
Gene; 1988 Dec; 72(1-2):343-7. PubMed ID: 3243433
[TBL] [Abstract][Full Text] [Related]
62. Application of antisense technology to therapeutics.
Heidenreich O; Kang SH; Xu X; Nerenberg M
Mol Med Today; 1995 Jun; 1(3):128-33. PubMed ID: 9415148
[TBL] [Abstract][Full Text] [Related]
63. Oligonucleotides as inhibitors of human immunodeficiency virus.
Field AK
Curr Opin Mol Ther; 1999 Jun; 1(3):323-31. PubMed ID: 11713797
[TBL] [Abstract][Full Text] [Related]
64. Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides.
Detrick B; Nagineni CN; Grillone LR; Anderson KP; Henry SP; Hooks JJ
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):163-9. PubMed ID: 11133862
[TBL] [Abstract][Full Text] [Related]
65. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision.
Orr RM
Curr Opin Mol Ther; 2001 Jun; 3(3):288-94. PubMed ID: 11497353
[TBL] [Abstract][Full Text] [Related]
66. Phosphorothioate G3T4G3 motifs inhibits the early stage of HIV-1 infection.
Suzuki J; Miyano-Kurosaki N; Takeuchi H; Tamura Y; Kawai G; Takai K; Tanaka Y; Tanaka R; Yamamoto N; Takaku H
Nucleic Acids Symp Ser; 1999; (42):227-8. PubMed ID: 10780462
[TBL] [Abstract][Full Text] [Related]
67. [Inhibition of reproduction of the human immunodeficiency virus by sense and antisense oligodeoxynucleotides].
Pokrovskiĭ AG; Pliasunova OA; Blinov VM; Vlasov VV; Svinarchuk FP; Abramova TV; Gorn VV; Konevets DA
Mol Biol (Mosk); 1993; 27(5):1039-43. PubMed ID: 8246927
[TBL] [Abstract][Full Text] [Related]
68. Inhibition of HIV-1 replication by a new type of circular dumbbell RNA/DNA chimeric oligonucleotides.
Park WS; Miyano-Kurosaki N; Abe T; Takai K; Yamamoto N; Takaku H
Biochem Biophys Res Commun; 2000 Apr; 270(3):953-60. PubMed ID: 10772932
[TBL] [Abstract][Full Text] [Related]
69. Hepatitis C IRES: translating translation into a therapeutic target.
Jubin R
Curr Opin Mol Ther; 2001 Jun; 3(3):278-87. PubMed ID: 11497352
[TBL] [Abstract][Full Text] [Related]
70. A monoclonal antibody extends the half-life of an anti-HIV oligodeoxynucleotide and targets it to CD4+ cells.
Morelli D; Pozzi B; Maier JA; Ménard S; Colnaghi MI; Balsari A
Nucleic Acids Res; 1995 Nov; 23(22):4603-7. PubMed ID: 8524649
[TBL] [Abstract][Full Text] [Related]
71. Phosphorothioate antisense oligodeoxynucleotides capable of inhibiting hepatitis C virus gene expression: in vitro translation assay.
Seki M; Honda Y
J Biochem; 1995 Dec; 118(6):1199-204. PubMed ID: 8720135
[TBL] [Abstract][Full Text] [Related]
72. Limited use of cationic liposomes as tools to enhance the antiherpetic activities of oligonucleotides in vero cells infected with herpes simplex virus type 1.
Shoji Y; Norimatsu M; Shimada J; Mizushima Y
Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):255-63. PubMed ID: 9743464
[TBL] [Abstract][Full Text] [Related]
73. Inhibition of HIV-1 replication by foldback triple-helix forming oligonucleotides.
Hiratou T; Tsukahara S; Takai K; Koyanagi Y; Yamamoto N; Takaku H
Nucleic Acids Symp Ser; 1997; (37):221-2. PubMed ID: 9586079
[TBL] [Abstract][Full Text] [Related]
74. Antisense oligodeoxynucleotides.
Stein CA; Narayanan R
Curr Opin Oncol; 1994 Nov; 6(6):587-94. PubMed ID: 7827170
[TBL] [Abstract][Full Text] [Related]
75. Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-alpha and the epidermal growth factor receptor.
Rubenstein M; Glick R; Lichtor T; Mirochnik Y; Chou P; Guinan P
Med Oncol; 2001; 18(2):121-30. PubMed ID: 11778757
[TBL] [Abstract][Full Text] [Related]
76. The therapeutic potential of antisense oligonucleotides.
Sharma HW; Narayanan R
Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
[TBL] [Abstract][Full Text] [Related]
77. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.
Geary RS; Leeds JM; Henry SP; Monteith DK; Levin AA
Anticancer Drug Des; 1997 Jul; 12(5):383-93. PubMed ID: 9236854
[No Abstract] [Full Text] [Related]
78. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines.
Wagner RW; Matteucci MD; Lewis JG; Gutierrez AJ; Moulds C; Froehler BC
Science; 1993 Jun; 260(5113):1510-3. PubMed ID: 7684856
[TBL] [Abstract][Full Text] [Related]
79. Antisense strategy: biological utility and prospects in the treatment of hematological malignancies.
Warzocha K; Wotowiec D
Leuk Lymphoma; 1997 Jan; 24(3-4):267-81. PubMed ID: 9156656
[TBL] [Abstract][Full Text] [Related]
80. Is antisense an appropriate nomenclature or design for oligodeoxynucleotides aimed at the inhibition of HIV-1 replication?
Lavigne C; Yelle J; Sauve G; Thierry AR
AAPS PharmSci; 2002; 4(2):E9. PubMed ID: 12102618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
